RTIL 13

• UNSPSC Description:

  RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 μM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively[1][2].

• Target Antigen:

  Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/rtil-13.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1[C@@]2([H])[C@](C(N1CC[N+](C)(C)CCCCCCCCCCCCCCCCCC)=O)([H])[C@H]3O[C@@H]2CC3.[Br-]

• Molecular Weight:

  571.67

• References & Citations:

  [1]Zhang J, et, al. From Spanish fly to room-temperature ionic liquids (RTILs): synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs. New Journal of Chemistry. 2008 Jan; 32(1): 1-180.|[2]Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of Newcastle. Tuesday, December 28, 2021.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1009376-10-6